0000005069 00000 n Abrupt withdrawal of alcohol, benzodiazepines, barbiturates, or antiepileptics. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. or elimination may be expected to influence the degree and extent of accumulation of the active metabolites of bupropion. The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled … ≥18yrs: initially 150mg once daily in the AM for at least 3 days; if tolerated, increase to 150mg twice daily at least 8hrs apart. 157 0 obj <> endobj Therapy with Wellbutrin SR may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue.The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with Wellbutrin SR is unclear. 0000005390 00000 n This section provides information on the proper use of a number of products that contain bupropion. Levodopa, amantadine may increase CNS toxicity. Instruct patients if they miss a dose, not to take an extra tablet to make up for the missed dose and to take the next tablet at the regular time because of the dose-related risk of seizure. startxref Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible Educate patients that WELLBUTRIN SR contains the same active ingredient (bupropion hydrochloride) found in ZYBAN, which is used as an aid to smoking cessation treatment, and that WELLBUTRIN SR should not be used in combination with ZYBAN or any other medications that contain bupropion (such as WELLBUTRIN, the immediate-release formulation and WELLBUTRIN XL or FORFIVO XL, the extended-release formulations, and APLENZIN, the extended-release formulation of bupropion hydrobromide). Initial U.S. Approval: 1985 . Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. 0000001586 00000 n It is important for you to follow-up with your healthcare provider until your symptoms go away.

You can ask your healthcare provider or pharmacist for information about Wellbutrin SR that is written for healthcare professionals.For more information about Wellbutrin SR, call 1-888-825-5249.Inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide. Do not chew, divide, or crush tablets; they are designed to slowly release drug in the body. 0000002670 00000 n The molecular formula is CWELLBUTRIN SR is supplied for oral administration as 100‑mg (blue), 150‑mg (purple), and 200‑mg (light pink), film‑coated, sustained‑release tablets. In patients with mild hepatic impairment (Child-Pugh score: 5 to 6), consider reducing the dose and/or frequency of dosing Consider reducing the dose and/or frequency of Wellbutrin SR in patients with renal impairment (Glomerular Filtration Rate less than 90 mL/min) At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with Wellbutrin SR. Conversely, at least 14 days should be allowed after stopping Wellbutrin SR before starting an MAOI antidepressant Do not start Wellbutrin SR in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue. %%EOF In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.No increased risk for cardiovascular malformations overall has been observed after bupropion exposure during the first trimester.

At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of treatment with Wellbutrin SR. Conversely, at least 14 days should be allowed after stopping Wellbutrin SR before starting an MAOI antidepressant False-positive urine immunoassay screening tests for amphetamines have been reported in patients taking bupropion. 0000008213 00000 n 0000004235 00000 n